See more : GOBLIN INDIA LIMITED (GOBLIN.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Biora Therapeutics, Inc. (BIOR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Biora Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Country Garden Holdings Company Limited (CTRYY) Income Statement Analysis – Financial Results
- California Water Service Group (CWT) Income Statement Analysis – Financial Results
- Home Bancshares, Inc. (Conway, AR) (HOMB) Income Statement Analysis – Financial Results
- Bang & Olufsen a/s (0MRM.L) Income Statement Analysis – Financial Results
- 2seventy bio, Inc. (TSVT) Income Statement Analysis – Financial Results
Biora Therapeutics, Inc. (BIOR)
About Biora Therapeutics, Inc.
Biora Therapeutics, Inc., a biotechnology company, engages in developing oral biotherapeutics. The company's targeted therapeutics program uses an ingestible smart capsule for targeted delivery of therapeutics in the gastrointestinal (GI) tract to enhance the treatment of inflammatory bowel diseases; and systemic therapeutics program uses an ingestible capsule for needle-free delivery of biotherapeutics directly into the intestinal mucosa for enhanced systemic uptake. It is also developing diagnostics devices to help characterize the GI tract and diagnose GI diseases, such as small intestine bacterial overgrowth through the development of various technologies to diagnose at the site of the disease. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 4.00K | 305.00K | 1.25M | 74.31M | 143.99M | 127.97M |
| Cost of Revenue | 0.00 | 907.00K | 1.44M | 93.43M | 100.49M | 92.08M |
| Gross Profit | 4.00K | -602.00K | -190.00K | -19.12M | 43.49M | 35.90M |
| Gross Profit Ratio | 100.00% | -197.38% | -15.24% | -25.73% | 30.21% | 28.05% |
| Research & Development | 29.84M | 24.05M | 45.79M | 47.74M | 63.40M | 48.71M |
| General & Administrative | 0.00 | 0.00 | 68.54M | 75.44M | 61.32M | 51.24M |
| Selling & Marketing | 0.00 | 0.00 | 4.76M | 52.89M | 58.89M | 50.19M |
| SG&A | 37.31M | 38.04M | 73.30M | 128.33M | 120.21M | 101.43M |
| Other Expenses | 0.00 | 2.62M | 5.99M | -25.08M | 0.00 | 0.00 |
| Operating Expenses | 67.15M | 62.09M | 119.08M | 176.07M | 183.61M | 150.14M |
| Cost & Expenses | 67.15M | 62.09M | 119.08M | 269.50M | 284.10M | 242.21M |
| Interest Income | 0.00 | 10.99M | 12.64M | 9.92M | 575.00K | 1.80M |
| Interest Expense | 9.82M | 10.99M | 12.64M | 34.87M | 9.20M | 9.09M |
| Depreciation & Amortization | 555.00K | 907.00K | 1.44M | 1.44M | 4.60M | 4.60M |
| EBITDA | -114.05M | -37.35M | -164.57M | -106.18M | -135.44M | -110.17M |
| EBITDA Ratio | -2,851,350.00% | -19,398.03% | -5,106.66% | -262.66% | -92.51% | -84.93% |
| Operating Income | -67.14M | -61.78M | -117.84M | -195.19M | -140.12M | -114.24M |
| Operating Income Ratio | -1,678,575.00% | -20,256.07% | -9,449.64% | -262.66% | -97.31% | -89.27% |
| Total Other Income/Expenses | -57.28M | 12.53M | -60.80M | -35.00M | -8.62M | -9.62M |
| Income Before Tax | -124.42M | -49.25M | -178.64M | -230.06M | -148.74M | -123.86M |
| Income Before Tax Ratio | -3,110,600.00% | -16,147.54% | -14,325.58% | -309.58% | -103.30% | -96.78% |
| Income Tax Expense | -90.00K | -420.00K | -119.00K | -37.53M | -706.00K | 5.25M |
| Net Income | -124.12M | -48.83M | -178.52M | -192.53M | -148.04M | -129.11M |
| Net Income Ratio | -3,102,875.00% | -16,009.84% | -14,316.04% | -259.08% | -102.81% | -100.88% |
| EPS | -7.87 | -6.40 | -46.42 | -86.30 | -80.17 | -119.71 |
| EPS Diluted | -7.87 | -6.40 | -46.42 | -86.30 | -80.17 | -119.71 |
| Weighted Avg Shares Out | 15.77M | 7.64M | 3.85M | 2.23M | 1.85M | 1.08M |
| Weighted Avg Shares Out (Dil) | 15.77M | 7.64M | 3.85M | 2.23M | 1.85M | 1.08M |
Biora Therapeutics Presents Data on the BioJet™ Systemic Oral Delivery Platform at the 59th Annual Meeting of the European Association for the Study of Diabetes
Biora Therapeutics Announces Submission of IND Application to the U.S. FDA for BT-600 Program
Hidden Gems: 3 Penny Stocks Flying Under the Radar.
Biora Therapeutics Reduces Debt and Largest Shareholder Increases Equity Exposure
Biora Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference
Biora Therapeutics Progresses its BioJet™ Systemic Oral Delivery Platform
Biora Therapeutics, Inc. (BIOR) Q2 2023 Earnings Call Transcript
Biora Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results
Biora Therapeutics Announces New Patents Covering its BioJet™ Systemic Oral Delivery Platform
Biora Therapeutics to Participate in Canaccord Genuity 43rd Annual Growth Conference
Source: https://incomestatements.info
Category: Stock Reports